Ilico Genetics develops advanced diagnostic technologies that make early cancer detection accessible and precise. Our flagship innovation, GastroMDx™, uses a simple blood test to identify stomach cancer in its earliest stages — years before symptoms typically appear.

The test is intended for individuals at higher risk for gastric cancer, such as those with a family history, chronic gastritis, Helicobacter pylori infection, or living in regions where gastric cancer rates are high. Your healthcare provider can help determine if GastroMDx is right for you.

In its pilot study of 89 patients, GastroMDx achieved 99% accuracy, 100% specificity, and 97% sensitivity, demonstrating exceptional reliability in detecting early gastric cancer markers.

The process is quick and non-invasive — it only requires a standard blood draw. The sample is analyzed in a certified laboratory using Ilico’s proprietary predictive model to identify molecular patterns linked to early-stage gastric cancer.

Ilico Genetics is completing regulatory and clinical validation steps to make the test available to healthcare providers. Updates on availability will be shared as the test moves toward broader clinical use.